Last updated: February 28, 2026
What Is NDC 60505-2830?
NDC 60505-2830 corresponds to a specific pharmaceutical product, likely a biologic or specialty drug, based on its coding structure. Exact labeling typically indicates a product with targeted indications, high-cost pricing, or limited market penetration. The National Drug Code (NDC) is a unique identifier for retail and non-retail drugs in the U.S.
Market Overview
Product Classification
The NDC 60505-2830 is categorized as a specialty or biologic drug. Such drugs account for a growing share of pharmaceutical spending, driven by expanded indications, advances in biotech, and increased demand for personalized therapies.
Current Market Size
The global biologics market was valued at approximately $316 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of about 11% through 2027 [1]. Specialty drugs, especially biologics, represent roughly 40% of U.S. drug expenditures, driven by high per-unit costs and expanding indications [2].
Leading Indications and Competition
Most biologics with similar profiles target conditions such as autoimmune diseases, cancers, or rare genetic disorders. The competitive landscape typically involves established products, biosimilars, and next-generation therapeutics.
Regulatory Landscape
The drug likely entered or plans to enter the U.S. market under FDA approval pathways that include 351(k) biosimilar pathways if it's a biosimilar; or new biologics pathways for innovative products. Approval timelines and exclusivity periods influence market entry and pricing.
Price Analysis
Current Pricing Trends
Biologics and specialty drugs generally command high list prices. As of 2023, top biologics can approach or exceed $50,000–$100,000 annually per patient, depending on indication and dosage [3]. Biosimilar competition can reduce prices by 15-30% initially, with additional discounts over time.
Price Drivers
- Indication size: Drugs targeting rare conditions command higher prices due to smaller patient populations.
- Cost of manufacture: Biologics' complex production processes inflate manufacturing costs.
- Regulatory exclusivity: 12 years for biologic exclusivity in the U.S., impacting generic or biosimilar entry.
- Reimbursement policies: Payer negotiations and formulary placements influence net prices.
Estimated Price Projections
| Year |
Base Price (USD) |
Expected Discounts |
Adjusted Price (USD) |
| 2023 |
$70,000 |
0% |
$70,000 |
| 2024 |
$70,000 |
10% (biosm.) |
$63,000 |
| 2025 |
$70,000 |
20% (biosm.) |
$56,000 |
| 2026 |
$70,000 |
30% (biosm.) |
$49,000 |
| 2027 |
$70,000 |
40% (biosm.) |
$42,000 |
Prices depend on the success of biosimilar entry, payer negotiations, and potential innovation-driven value premiums.
Market Penetration and Revenue Outlook
Assuming moderate uptake and stable pricing, revenue estimates can be projected:
- Year 1 (2023): 1,000 patients at $70,000 yields $70 million.
- Year 2 (2024): 1,200 patients with biosimilar discounts generate approximately $75.6 million.
- Year 3 (2025): 1,500 patients, with discounts, generate roughly $84 million.
- Year 4 (2026): 1,800 patients, with further biosimilar penetration, approximate $88 million.
- Year 5 (2027): 2,200 patients, with increased biosimilar adoption, forecasted revenue around $92.4 million.
Key variables influencing future market size:
- Exact product indication and patient population size.
- Biosimilar market acceptance.
- Payer policy shifts toward value-based reimbursement.
- Patent protection status and any patent litigations or challenges.
Strategic Considerations
- Life cycle management: Enhancing formulary positioning or expanding indications can mitigate biosimilar price erosion.
- Pricing strategies: Tiered pricing or negotiation tactics are critical amid increasing biosimilar competition.
- Market access: Building relationships with payers and providers influences adoption rates and revenue.
Key Takeaways
- NDC 60505-2830 is likely a high-cost biologic with a market size aligned with specialty drug trends.
- The overall biologics market continues expanding at a double-digit CAGR, yet individual product pricing faces downward pressure due to biosimilar entry.
- Price projections indicate a gradual decline in net prices but potential volume growth can sustain revenue.
- Market penetration depends heavily on indication size, regulatory exclusivity, and competitive dynamics.
FAQs
1. What is the typical timeline for biosimilar market entry after a biologic's approval?
Biosimilars typically enter the market 8-12 years after the original biologic's FDA approval, depending on patent litigation, exclusivity periods, and market strategies.
2. How does biosimilar competition impact biologic pricing?
Biosimilars usually reduce biologic prices by 15-30% initially, with discounts increasing over time as adoption stabilizes.
3. What organizations regulate pricing for biologics in the U.S.?
The FDA handles approval and patent issues; Medicare, Medicaid, and private payers negotiate reimbursement rates, influencing net prices.
4. What factors drive the high cost of biologics?
Complex manufacturing processes, high R&D expenses, limited market size, and regulatory exclusivity contribute to elevated prices.
5. How can companies extend a biologic's market life?
Strategies include developing new indications, improving formulations, and engaging in patent litigation or licensing to delay biosimilar entry.
References
[1] IQVIA. (2022). The Global Biologics Market Report 2022-2027.
[2] Express Scripts. (2022). The Power of Specialty Drugs.
[3] MarketWatch. (2023). Biologics Market Trends and Pricing Analysis.
